HYBRID EVENT: You can participate in person at Barcelona, Spain from your home or work.

10th Edition of World Congress on Infectious Diseases

June 25-27, 2026 | Barcelona, Spain

June 25 -27, 2026 | Barcelona, Spain
Infection 2025

COVID-19 vaccination strategies in the post-pandemic era

Speaker at Infectious Diseases Conferences - Pedro Plans Rubio
College of Physicians of Barcelona, Spain
Title : COVID-19 vaccination strategies in the post-pandemic era

Abstract:

COVID-19 vaccines have reduced the negative health and economic impact of the COVID.19 pandemic by preventing severe disease, hospitalizations and deaths. In the new socio-economic normality, the COVID-19 vaccination strategy can be universal or high-risk and seasonal or not seasonal, and different vaccines can be used. The universal vaccination strategy can achieve greater health and herd immunity effects and it is associated with greater costs than the high-risk vaccination strategy. In each country, the optimal COVID-19 vaccination strategy must be decided by considering the advantages and disadvantages and assessing the costs, health effects and cost-effectiveness of the universal and high-risk vaccination strategies. The universal vaccination strategy should be implemented when the objective of the vaccination program is to achieve the highest health benefits from COVID-19 vaccination and when its incremental cost-effectiveness ratio is lower than EUR30,000−50,000 per QALY or LYG. The use of adapted vaccines targeting currently circulating variants of SARS-CoV-2 is necessary to avoid the immune escape of emerging variants.

Biography:

Pedro Plans-Rubió has been Responsible for Health Registries, Public Health Agency of Catalonia, Barcelona, Spain (1999-2025). MD from the School of Medicine, University of Barcelona; PhD from the School of Medicine, University of Barcelona; MSc in Health Economics from the School of Economics, University of Barcelona. Specialist in Preventive Medicine and Public Health. Member of the Group of Prioritization of Treatments (GIP), Heath Emergency Preparedness and Response (HERA), European Commission. Member of the Non-communicable diseases risk factor Collaboration (NCD-RisC) research group. Editor-in Chief of Section “Vaccine Advancement, Efficacy and Safety” of journal Vaccines. Member of the Editorial Board of journal Pharmacoeconomics Open, Elsevier.

Watsapp